by Madaline Spencer | May 29, 2026
Logan Schneider, MD, Adjunct Clinical Associate Professor of Psychiatry and Behavioral Sciences at Stanford University, discusses the DUET clinical trial of Xywav (low sodium oxybate) in patients with narcolepsy. Narcolepsy is a chronic neurological...
by Madaline Spencer | May 28, 2026
Omar Sinno, MD, US Medical Strategy Lead for Rare Disease at UCB Pharma, discusses data presented on myasthenia gravis (MG) at the 2026 American Academy of Neurology meeting. MG is a chronic autoimmune neuromuscular disease characterized by weakness of...
by Madaline Spencer | May 26, 2026
Mauro Cives, MD, Associate Professor of Medical Oncology at the University of Bari, Italy, discusses the upcoming regulatory decision for LNTH-2501 to improve imaging of neuroendocrine tumors (NETs). NETs are rare tumors that usually develop in the...
by Madaline Spencer and James Radke, PhD | May 22, 2026
Pablo Villoslada, MD, PhD, Founder and Medical Director of Accure Therapeutics and Head of Pathogenesis and New Therapies MS at IDIBAPS in Hospital Clínic in Barcelona, discusses results from the ACUITY clinical trial testing privosegtor to treat patients with acute...
by Madaline Spencer | May 22, 2026
A recent publication in the Clinical Journal of the American Society of Nephrology presented outcomes of pegcetacoplan treatment in adolescents with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). C3G and IC-MPGN...
